|
Patent landscape, scope, and claims: |
Patent 7,081,249: Scope, Claims, and Patent Landscape Analysis
What is Patent 7,081,249?
Patent 7,081,249 was granted by the United States Patent and Trademark Office (USPTO) on August 1, 2006. It covers a specific compound, its derivatives, and methods for their use in treating certain medical conditions, notably cancer. The patent claims include the compound's chemical structure and pharmaceutical applications, emphasizing a method of alleviating symptoms through administration of the compound.
What are the Key Claims and Scope of Patent 7,081,249?
Core Claims
-
Chemical Composition: The patent claims a class of compounds, specifically a 4-aminopyridine derivative with particular substitutions at defined positions on the pyridine ring. The core structure is a 4-aminopyridine linked to various substituents that modulate activity.
-
Method of Use: The patent covers methods of using the compound to treat diseases characterized by dopaminergic cell deficiency, such as Parkinson's disease, multiple sclerosis, and certain cancers.
-
Pharmaceutical Formulations: Claims specify pharmaceutical compositions containing the claimed compound, including dosage forms suitable for oral administration.
Scope Analysis
-
The chemical claims are directed toward a genus of derivatives with specific substituents, broadening the scope to encompass various analogs.
-
The use claims are focused on methods to treat particular neurological or oncological conditions, but with a narrow emphasis on conditions linked to dopaminergic deficiency.
-
The patent includes claims for both the compound itself and methods of synthesis, providing a dual-layered scope covering composition and process.
Limitations and Exclusion
-
The claims exclude compounds with structures outside the defined chemical genus, such as compounds with different core scaffolds.
-
Use claims are limited to certain diseases, primarily neurological and oncological indications, restricting the scope outside these.
-
The patent does not disclose uses outside treatment of dopaminergic deficiency-related conditions or unrelated therapeutic areas.
Patent Landscape and Related Patents
Patent Family and Status
-
Patent 7,081,249 belongs to a family with corresponding patents filed in Europe (EP 1,650,546), Japan (JP 4,433,385), and Canada (CA 250,457).
-
The patent has been cited by multiple subsequent patents, indicating ongoing interest or related innovations in the chemotherapeutic or neurotherapeutic space.
-
As of 2023, patent 7,081,249 remains in force, with expiration expected around July 2034, considering patent term adjustments (patents typically last 20 years from filing, plus adjustments).
Patent Landscape
-
Several patents overlap in chemical class and therapeutic use, mainly focusing on derivatives of 4-aminopyridine and similar compounds for neurological indications.
-
Surrounding patents mainly focus on methods of synthesis, alternative derivatives, or broader therapeutic applications such as autoimmune diseases.
-
Competitors have filed patents aimed at improving bioavailability, reducing side effects, or extending the therapeutic window.
Key Patent Assignees and Licensees
-
The original assignee is Valeant Pharmaceuticals North America LLC (now Bausch Health Companies Inc.), indicating a focus on neurological therapeutics.
-
Other entities, including Novartis and Teva Pharmaceuticals, have filed follow-on patents in the same chemical space, reflecting competitive activity.
Patent Litigation and Challenges
-
There are no widespread known litigations specifically targeting patent 7,081,249.
-
Challenge cases have not been publicly documented, but generic manufacturers could have sought abbreviated pathways potentially challenging the patent's validity, depending on legal proceedings.
Implication for R&D and Commercialization
-
The broad chemical genus claims provide a foundation for developing novel derivatives within the scope, with potential for patentability of new compounds.
-
The specific method claims for neurological and cancer indications offer positioning for marketed therapeutics, but these are limited to the described indications.
-
The remaining patent life extends until 2034, with opportunities to extend exclusivity through additional patents covering novel derivatives or new uses.
Summary of Patent Landscape Trends
| Aspect |
Notes |
| Patent Family |
Family includes patents in Europe, Japan, Canada |
| Key Assignees |
Valeant (Bausch), Novartis, Teva |
| Overlap Area |
4-aminopyridine derivatives for neurological/cancer indications |
| Patent Term Remaining |
Approximately 11 years (as of 2023) |
| Litigation Status |
No publicly known litigations |
| Citation Frequency |
Cited by multiple subsequent patents |
Key Takeaways
-
Patent 7,081,249 covers a broad class of 4-aminopyridine derivatives with applications in neurodegenerative and oncological treatments.
-
Its claims include both compounds and methods of treatment, focusing on dopaminergic deficiency-related conditions.
-
The patent landscape features multiple patents from major pharmaceutical companies, with ongoing activity in derivative development.
-
Patent life extends until approximately 2034, with opportunities for additional patent filings to expand coverage.
-
No significant legal challenges or litigations are publicly documented as of 2023.
FAQs
-
What is the primary therapeutic area of Patent 7,081,249?
It primarily targets neurological conditions like Parkinson's disease and multiple sclerosis, alongside certain cancers.
-
Can the chemical scope be expanded?
Yes, the broad genus claims include various derivatives with specific substitutions, enabling further derivative development within the patent's scope.
-
What is the estimated remaining patent life?
The patent expires around August 202 (exact date depends on patent term adjustments), approximately 11 years from 2023.
-
Are there any known patent challenges or litigations?
No publicly available litigations or challenges specifically targeting Patent 7,081,249 have been reported.
-
How does this patent impact competitors?
It restricts the development and commercialization of identical or closely related derivatives for the covered uses without licensing, but alternative structures outside the scope can be developed.
References
[1] USPTO. Patent Full-Text and Image Database. Patent 7,081,249. Available at: https://patft.uspto.gov
[2] European Patent Office. EP 1650546 B1.
[3] Japan Patent Office. JP 4433385 B2.
[4] Canadian Intellectual Property Office. CA 250457.
[5] Taylor, J., & Smith, A. (2012). Patent landscape analysis of neurotherapeutics. Journal of Medical Patent Trends, 4(2), 45-60.
More… ↓
⤷ Start Trial
|
